Hims & Hers brought in $1.48 billion in revenue in 2024, up 69% year over year from $872 million in 2023, the company reported in its fourth-quarter and full-year earnings report
Other companies are working on their own weight-loss pills: Eli Lilly, which makes Zepbound, is developing a GLP-1 pill, orforglipron, for weight loss and type 2 diabetes, with FDA approval anticipated for March 2026
Obesity wonder drugs Wegovy and Zepbound are already showing that they can reduce the risk of cardiovascular and chronic kidney disease in addition to helping people lose weight
Because free radical damage is at the heart of all cellular ageing and chronic disease, insufficient glutathione can be connected with all kinds of ill-health
Roslan J, Giribabu N, Karim K, Salleh N
Aging is really not that complicated once you understand the genes that control it, says David Sinclair, a top longevity researcher at Harvard Medical School